Mechanisms of ventricular rate adaptation as a predictor of arrhythmic risk

Esther Pueyo,1,2,3 Zoltán Hústi,4 Tibor Hornyik,4,5 István Baczkó,4 Pablo Laguna,2,3 András Varró,4,5 and Blanca Rodríguez1

1Oxford University Computing Laboratory, University of Oxford, Oxford, United Kingdom; 2Instituto de Investigación en Ingeniería de Aragón, Universidad de Zaragoza, Zaragoza, Spain; 3Centro de Investigación Biológica En Red de Bioingeniería, Biomateriales y Nanomedicina, Zaragoza, Spain; and 4Department of Pharmacology and Pharmacotherapy, University of Szeged, and 5Research Unit for Cardiovascular Pharmacology, Hungarian Academy of Sciences, Szeged, Hungary

Submitted 5 October 2009; accepted in final form 23 February 2010

Pueyo E, Hústi Z, Hornyik T, Baczkó I, Laguna P, Varró A, Rodríguez B. Mechanisms of ventricular rate adaptation as a predictor of arrhythmic risk. Am J Physiol Heart Circ Physiol 298: H1577–H1587, 2010. First published March 5, 2010; doi:10.1152/ajpheart.00936.2009.—Protracted QT interval (QTI) adaptation to abrupt heart rate (HR) changes has been identified as a clinical arrhythmic risk marker. This study investigates the ionic mechanisms of QTI rate adaptation and its relationship to arrhythmic risk. Computer simulations and experimental recordings in human and canine ventricular tissue were used to investigate the ionic basis of QTI and action potential duration (APD) to abrupt changes in HR with a protocol commonly used in clinical studies. The time for 90% QTI adaptation is 3.5 min in simulations, in agreement with experimental and clinical data in humans. APD adaptation follows similar dynamics, being faster in midmyocardial cells (2.5 min) than in endocardial and epicardial cells (3.5 min). Both QTI and APD adapt in two phases following an abrupt HR change: a fast initial phase with time constant < 30 s, mainly related to L-type calcium and slow-delayed rectifier potassium current, and a second slow phase of > 2 min driven by intracellular sodium concentration ([Na+]s) dynamics. Alterations in [Na+]s, dynamics due to Na+/K+ pump current inhibition result in protracted rate adaptation and are associated with increased proarrhythmic risk, as indicated by action potential triangulation and faster L-type calcium current recovery from inactivation, leading to the formation of early afterdepolarizations. In conclusion, this study suggests that protracted QTI adaptation could be an indicator of altered [Na+]s, dynamics following Na+/K+ pump inhibition as it occurs in patients with ischemia or heart failure. An increased risk of cardiac arrhythmias in patients with protracted rate adaptation may be due to an increased risk of early afterdepolarization formation.

The present study investigates the ionic basis of QTI rate adaptation in human ventricular tissue and its link to proarrhythmic mechanisms. Computer simulations and experiments were conducted to identify the specific mechanisms of ionic transport that determine QTI rate adaptation and how alterations in those mechanisms might result in arrhythmic events. Key simulation predictions were evaluated using experimental and clinical data from the literature and a limited set of experiments in humans performed in this study. Ionic mechanisms underlying HR adaptation were further investigated using simulations and experiments in both humans and dogs because of their similar repolarization mechanisms and the greater availability of canine tissue compared with that of humans (41).

MATERIALS AND METHODS

Computer Modeling and Simulation

Human (38) and canine (10) ventricular cell models were used to investigate short-term memory mechanisms. Computer simulations of electrical propagation and pseudo-ECG (pECG) (21) were conducted using a transmural one-dimensional fiber model, consisting of 100 cells [30% endocardial (Endo), 30% midmyocardial (Mid), and 40% epicardial (Epi) cells (12, 38)]. A 1-ms diastolic threshold was applied to the endocardium. Integration was performed using the forward Euler method with a 0.02-ms time step and 0.015-cm space step. pECG peaks and boundaries were identified using an automatic wavelet transform-based delineation system (33). pECG QTI was measured as the time interval between the QRS complex onset and the T-wave end.

Characterization of Ventricular HR Adaptation Dynamics

The rate adaptation of QTI and action potential (AP) duration (APD) at 90% repolarization was evaluated (18, 29): pacing at a cycle length (CL) of 1,000 ms was applied until steady state, followed by a CL of 600 ms for 10 min and back to a CL of 1,000 ms for an additional 10 min. Fast and slow phases in QTI and APD rate adaptation were identified, and time constants (τ) of their dynamics were obtained by fitting to: f(t) = a + be−(t−c)/τ,

Time constants τfast and τslow, characterizing each of the two adaptation phases, were obtained, both after the CL increase and decrease. In cases where the fast phase consisted of only two data points, then f(t) = be−t/τ was used to derive τfast.

QTI or APD adaptation is defined as protracted when the associated time constant τslow is abnormally long (see RESULTS for a detailed description), which is related to irregularities in APD adaptation dynamics and the generation of afterdepolarizations.

Evaluation of Proarrhythmic Risk in Simulation

To investigate the ionic mechanisms of rate adaptation and its relationship to risk, adaptation dynamics and arrhythmic risk markers
were quantified for control and also following ±15 and ±30% changes in specific model parameters. The arrhythmic risk markers (30) considered were 1) AP triangulation, quantified as δ = APD/ \( APD_{50} \) where \( APD_{50} \) denotes APD at 50% repolarization, considered to be an indicator of an early afterdepolarization (EAD) occurrence (34); 2) APD restitution (APDR) curve slope at a diastolic interval of 60 ms (26), determined using both S1-S2 and dynamic protocols (38), \( S_{21-S2} \) and \( S_{50n} \), respectively; and 3) calcium current reactivation, as the product of the inactivation gates \( f_i, f_2, \) and \( f_{cass} \) (38)) of the L-type calcium current \( (I_{CaL}) \) computed at 90% repolarization for steady state at a CL of 1,000 ms (42).

Experimental Methods

Experiments were performed to validate key simulation results, when specific data were not available in the literature. Experiments were conducted in human ventricular tissue when available \((n = 2\) tissue samples); otherwise, right ventricle papillary muscles isolated from adult mongrel dogs hearts \((n = 21)\) were used \((8–20\) kg, either sex) (40). All animal experiments were conducted in compliance with the Guide for the Care and Use of Laboratory Animals (NIH Publication No. 85-23, Revised 1996), and the protocol was approved by the Ethical Committee for the Protection of Animals in Research of the University of Szeged, Hungary (No. 1-74-125-2007). Human right ventricular papillary muscle preparations were dissected from donor hearts stored in cardioplegic solution at 4°C for 3 to 4 h before placing them into oxygenated modified Locke’s solution containing \((mM) 120\) NaCl, 4 KCl, 1.0 CaCl\(_2\), 1 MgCl\(_2\), 22 NaHCO\(_3\), and 11 glucose. The pH of this solution was set to 7.4 ± 0.05 when saturated with the mixture of \(95%\) O\(_2\) and \(5%\) CO\(_2\) at 37°C.

Transmembrane APs were recorded using the conventional microelectrode technique as described previously (40). APD HR adaptation was evaluated using the same protocol as in the simulations, both in control (in humans and dogs) and in the presence of the following drug concentrations (in dogs): 0.2 and \(0.6\) μM strophanthin G \((n = 5\) and 7), \(1\) and \(3\) μM nisoldipine \((n = 1)\), \(30\) μM BaCl\(_2\) \((n = 2)\), \(0.25\) μM HMR-1556 \((n = 3)\), and \(0.1\) μM doxetilide \((n = 3)\). Strophanthin G and BaCl\(_2\) were dissolved in distilled water to give stock solution concentrations of \(1\) and \(50\) mM, respectively. Nisoldipine was dissolved in \(100\%\) ethanol stock solution \((1\) mM). HMR-1556 was dissolved in DMSO stock solution \((1\) mM).

RESULTS

Ventricular Rate Adaptation

QTI adaptation. Figure 1A illustrates QTI adaptation kinetics in humans from simulations (left) and clinical data (29) (right). Figure 1B shows simulated pECG for the first beat following HR acceleration (left) and deceleration (right) and when the new steady state is reached. QTI adaptation after a

<table>
<thead>
<tr>
<th>Simulation</th>
<th>TP06</th>
<th>HRacc: 217 s</th>
<th>HRdec: 224s</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lau et al</td>
<td>HRAcc, mean ± SEM: 136 ± 16 s</td>
<td>HRdec, mean ± SEM: 189 ± 25 s</td>
<td></td>
</tr>
<tr>
<td>Seed et al</td>
<td>&gt;180 s</td>
<td>~180 s</td>
<td></td>
</tr>
<tr>
<td>Attwell et al</td>
<td>60 s – 300 s</td>
<td>10 s – 240 s</td>
<td></td>
</tr>
<tr>
<td>Grom et al</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Puyo et al</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Fig. 1. A, left: simulated QT interval (QTI) adaptation in human pseudo-ECG for cycle length (CL) of 1,000 to 600 to 1,000 ms. A, right: QTI adaptation in human ECG recordings for 50 or 110 beats/min in increments or decrements of 20, 40, and 60 beats/min (modified and redrawn from original graphs from Ref. 29). Time required for 90% QTI rate adaptation \((t_{90})\) is presented. B: simulated pseudo-ECGs corresponding to first (dotted line) and last (solid line) beats after CL decrease (left) and CL increase (right). C: \(t_{90}\) values for simulated pseudo-ECGs and clinical human ECGs. HR, heart rate; Acc, acceleration; Dec, deceleration; TP06, human ventricular cell model developed by ten Tusscher and Panfilov (38) in 2006.
step CL decrease/increase begins with a fast QTI shortening/lengthening during the initial beats after the HR change (t_{fast} = 17/34 s), followed by a second slow accommodation (t_{slow} = 122/122 s). In the simulations, the time (t_{90}) required for QTI to complete 90% of its adaptation in humans is 217/224 s following HR acceleration/deceleration. As shown in Fig. 1C, simulation values for t_{90} are within the wide range reported clinically.

A sensitivity analysis was performed to assess the dependence of QTI rate adaptation dynamics on CL change magnitude (m_{CL}) and on the initial CL (i_{CL}). Values for m_{CL} considered were 200, 400, and 600 ms, and values for i_{CL} were 1,000 and 1,400 ms. No statistically significant differences (analysis of variance, P > 0.05) in t_{90} are observed when varying m_{CL} or i_{CL}.

APD adaptation. Figure 2, A and B, illustrates APD HR adaptation in simulated Endo (top), Mid (middle), and Epi (bottom) human ventricular cells. Figure 2A shows the time course of APD adaptation, and Fig. 2B illustrates the AP corresponding to the first beat and the new steady state following HR acceleration/deceleration.

Fig. 2. A: simulated action potential (AP) duration (APD) adaptation in humans for CL of 1,000 to 600 to 1,000 ms for endocardial (Endo; top), midmyocardial (Mid; middle), and epicardial (Epi; bottom) cardiomyocytes. B: simulated APs corresponding to first (dotted line) and last (solid line) beats after CL decrease (left) and CL increase (right) for human Endo (top), Mid (middle), and Epi (bottom) cardiomyocytes. C: experimental APD adaptation in humans for CL of 750–410 ms (left, modified and redrawn from original graphs from Ref. 18) and for CL of 1,000–600 ms (right, this study). D: t_{90} values for simulated and experimental human APs.
ing HR acceleration (left) and deceleration (right) for the three cell types. Figure 2C presents experimental APD adaptation measured in human ventricular endocardium (18), as well as in human papillary muscle, measured in this study.

It is clear that APD HR adaptation dynamics are similar in human simulations and experiments (18) and comparable with QTI HR adaptation dynamics (shown in Fig. 1), consisting of a fast and slow phase \( \tau_{\text{fast}} = 13/26 \text{ s after CL decrease/increase for Endo, 6/14 \text{ s for Mid, and 13/26 \text{ s for Epi cells; and } } \tau_{\text{slow}} = 126/122 \text{ s after CL decrease/increase for Endo, 128/122 \text{ s for Mid, and 126/123 \text{ s for Epi cells).} This suggests that QTI HR adaptation is a manifestation of cellular APD HR adaptation. As shown in Fig. 2D, simulation values for \( t_{90} \) are within the range observed experimentally. Furthermore, simulations with both the human and the dog models yield similar rate adaptation dynamics, although slightly slower in dog (\( t_{90} = 282/311 \text{ s in canine and } t_{90} = 213/218 \text{ s in human Epi cells for HR acceleration/deceleration, respectively). Analogous to the results reported for QTI in this study, no statistically significant differences in } t_{90} \text{ for APD adaptation are found when varying } m_{\text{CL}} \text{ or } i_{\text{CL}}. \)

Ionic Mechanisms of APD Rate Adaptation

Figures 3 and 4 illustrate the ionic mechanisms of APD HR adaptation in humans. Each panel in Fig. 3 represents the change in peak value of each ionic current [slow delayed rectifier potassium current \( (I_{Ks}) \), \( I_{\text{CaL}} \), transient outward potassium current \( (I_{to}) \), rapid delayed rectifier potassium current \( (I_{Kr}) \), inward rectifier potassium current \( (I_{Kr}) \), fast sodium current \( (I_{Na}) \), Na\(^+\)/Ca\(^2+\) exchanger current \( (I_{NaCa}) \), and Na\(^+\)/K\(^+\) pump current \( (I_{NaK}) \)] or intracellular sodium and calcium ion concentration ([Na\(^+\)], [Ca\(^2+\)]) as a function of APD for the beats following HR acceleration (analogous results were obtained for HR deceleration; graphics not shown). The numbers shown in each graph indicate the number of beats following the CL change. Bar graphs in Fig. 4 show the percentage of total change in peak values of each ionic current or intracellular ion concentration that occurred during the fast (top) and slow (bottom) phase of HR adaptation. The ionic mechanisms involved in each of the adaptation phases, fast and slow, are further described in the following.

**Initial fast phase of adaptation.** Figures 3 and 4 show that \( I_{\text{CaL}} \) and \( I_{Ks} \) experience the greatest percentage of total change during the initial phase of rate adaptation and are key mechanisms driving that phase. Other ionic currents, such as \( I_{to} \), present a percentage of change similar to \( I_{Ks} \), but these changes are a consequence (and not a cause) of APD adaptation, since variations in conductance and/or kinetics do not affect \( \tau_{\text{fast}}. \)

Figure 5A further illustrates the role that the dynamics of the \( I_{\text{CaL}} \) slow voltage-dependent inactivation gate (\( f \)) and the \( I_{Ks} \)
activation gate (xs) play in the fast phase of human APD adaptation. Indeed, a sudden decrease in CL results in an insufficient time for f to fully recover (f < 1) (Fig. 5A, top), whereas Ik is unable to completely deactivate (xs > 0) at the end of each beat. The resulting decrease in inward and increase in outward currents contribute to APD shortening following HR acceleration. To further illustrate the importance of f and xs in the initial adaptation phase, Fig. 5A, right, shows APD adaptation dynamics for control and for a simulation where beat-to-beat differences in f and xs are eliminated by fixing them to their steady-state values for a CL of 1,000 ms (f = 0.9774 and xs = 0.003225, respectively). Results show that eliminating beat-to-beat differences in f and xs leads to the abolishment of the fast phase of APD adaptation. Similar mechanisms are observed using the canine ventricular model (not shown).

Simulations were performed to evaluate the effect of moderate changes (±15–30%) in values of key parameters defining gate kinetics and conductances of all ionic currents in the human ventricular model. The effect of those changes on time constants for the fast and slow adaptation phases (τfast and τslow), as well as the arrhythmic risk indicators ρ, δ, Ss1–Ss2, and Sdyn, were quantified. Simulation results are shown in Fig. 6 for the parameters with greatest influence on human APD HR adaptation. As previously discussed and illustrated in Figs. 3–5, Fig. 6 (first row) also shows that τfast is greatly sensitive to ICaL inactivation and Ik,s activation kinetics and thus moderate changes of up to 30% in τf and τxs significantly alter τfast. Changes of up to 30% in ionic current conductances have only a negligible effect on τfast (Fig. 6, first row). Additional simulations and experiments were conducted to evaluate whether large degrees (>70%) of ion channel block could affect τfast. Results for human ventricular myocyte simulations and canine experiments are shown in Fig. 7, left and right, respectively, for ICaL (A), Ik (B), Ik1 (C), and Ik (D). Results show that ICaL block by 70–90% significantly increases τfast by 54–249/107–223% following HR acceleration/deceleration using the human model (Fig. 7A, left). Qualitatively similar results are obtained using the canine model (not shown), although the effects are more pronounced in dogs, reaching >500% change in τfast for full ICaL block. In the experiments, ICaL block using 1 or 3 μM nisoldipine also results in increases τfast in canine papillary muscle (Fig. 7A, right), although to a lower extent than in the simulations, i.e., by 33/72% and 54/94% following HR acceleration/deceleration, respectively.

Furthermore, simulated 90–100% Ik,s inhibition results in a significant decrease in τfast by 71–82/63–76% following HR acceleration/deceleration in humans (Fig. 7B, left), whereas in dogs, the simulated effect is <10%. In the canine experiments, Ik,s block by 0.25 μM HMR-1556 (full block) led to 16/20% decrease in τfast following HR acceleration/deceleration (Fig. 7B, right). The effect of Ik1 and Ik block on τfast was also explored. The results in Fig. 7C, left, show that simulated Ik1 block by 80–90% results in a 6–40% decrease in τfast following HR acceleration/deceleration in humans, whereas in dogs it results in a 39–67/41–67% decrease in τfast. In the experiments, 30 μM BaCl2 (estimated 80% block) results in a 28/11% decrease in τfast (Fig. 7C, right). Full Ik block results in a 7/9% increase in τfast with the human model (Fig. 7D, left), but in the canine model this leads to EADs, making the τfast measurement impossible. In the canine experiments with 0.1 μM dofetilide, there is a 10/10% decrease in τfast following HR acceleration/deceleration (Fig. 7D, right). Overall, the simulations and experiments show a good qualitative agreement in the
effect of specific ionic current block on $\tau_{fast}$, although specific quantitative differences are found, which are further analyzed in DISCUSSION.

Slow phase of adaptation. APD adaptation finishes with a slow phase, during which $[\text{Na}^+]_i$ and $[\text{Ca}^{2+}]_i$, as well as $I_{\text{NaK}}$, $I_{\text{NaCa}}$, and several potassium currents, experience important changes (Figs. 3 and 4). As shown in Fig. 5B, left, following HR acceleration, $[\text{Na}^+]_i$ slowly accumulates (control trace), which causes an increase in repolarization current via enhanced activity of $I_{\text{NaK}}$ and $I_{\text{NaCa}}$ (operating in reverse mode), resulting in a progressive APD shortening. With the use of both human and canine ventricular models, clamping $[\text{Na}^+]_i$ to its steady-state value eliminates the slow APD adaptation phase (Fig. 5B, left), right). $I_{\text{CaL}}$ and $I_{\text{Ks}}$ block are also found to have an impact on the slow APD adaptation, although only in dogs, not in humans, and only for almost complete block. Specifically, 90% $I_{\text{Ks}}$ block leads to a $\sim 30\%$ decrease in $\tau_{slow}$ in both simulations and experiments in dogs but only to a $\sim 10\%$ decrease in human simulations. Full $I_{\text{Ks}}$ block is associated with a $\sim 25\%$ increase in $\tau_{slow}$ in experiments in dogs but results in a $<10\%$ change in $\tau_{slow}$ in humans. The effects of $I_{\text{CaL}}$, or $I_{\text{Ks}}$ block on $\tau_{slow}$ are negligible.

**APD HR Adaptation and Arrhythmic Risk**

In this section, the link between protracted QTI and APD HR adaptation dynamics and arrhythmic risk suggested by clinical studies (19, 35) is investigated. As shown in Fig. 6, fast $I_{\text{CaL}}$, inactivation and $I_{\text{Ks}}$ activation (i.e., decrease in $\tau_f$ or $\tau_x$, respectively) lead to large $\tau_{fast}$ values and to a simultaneously flattening of restitution curves, an enhanced AP triangulation (associated with increased risk of EAD development), and a decrease and an increase in $\rho$, respectively (protection against and increased likelihood of $I_{\text{CaL}}$ reactivation during AP repo-

---

**Fig. 6. Changes in time constants for fast ($\tau_{fast}$, first row) and slow ($\tau_{slow}$, second row) phases of APD adaptation (solid line for HR acceleration for CL of 1,000 to 600 ms, and dotted line for HR deceleration for CL of 600 to 1,000 ms), degree of $I_{\text{CaL}}$ recovery from inactivation at 90% repolarization ($\rho$, third row), AP triangulation ($\delta$, fourth row), S1-S2 restitution slope ($S_{S1-S2}$, fifth row), and dynamic restitution slope ($S_{dyn}$, sixth row) induced by $\pm 15–30\%$ variations in time constant of slow voltage-dependent $I_{\text{CaL}}$ inactivation gate $f$ ($\tau_f$, first column), time constant of $I_{\text{Ks}}$ activation gate $x$ ($\tau_x$, second column), $I_{\text{CaL}}$ maximal conductance ($G_{\text{CaL}}$, third column), $I_{\text{Ks}}$ maximal conductance ($G_{\text{Ks}}$, fourth column), and maximal $I_{\text{NaK}}$ ($G_{\text{NaK}}$, fifth column).**
larization, respectively). Despite the enhancement of AP triangulation associated with large $\tau_{\text{fast}}$ values, no afterdepolarizations were observed in the simulations for 60% changes in $g_f$, $g_s$, $I_{\text{CaL}}$ maximal conductance, and $I_{\text{Ks}}$ maximal conductance, although a 10-fold increase in $g_{\text{fast}}$ was obtained for a 60% reduction in $\tau_f$.

Regarding the slow phase of APD adaptation, Fig. 6 shows that $I_{\text{NaK}}$ inhibition results in an increase in $\tau_{\text{slow}}$ and also an increased $\rho$ and $\delta$, suggesting the increased likelihood of EAD generation (24, 27, 42). Indeed, $I_{\text{NaK}}$ inhibition by 30% in simulations and by 0.6 μM strophanthin G in experiments (A), $I_{\text{Ks}}$ block by 90–100% in simulations and by 0.25 μM HMR-1556 in experiments (B), $I_{\text{Kr}}$ block by 80–90% in simulations and by 30 μM BaCl$_2$ in experiments (C), and $I_{\text{K1}}$ block by 100% in simulations and by 0.1 μM dofetilide in experiments (D). All experimental curves represent average over experiments. Values for percent changes in the time constant of the fast phase of APD rate adaptation ($\tau_{\text{fast}}$) induced by each intervention are also shown.
Fig. 8. A: effect of Na⁺/K⁺ pump inhibition on the slow phase of APD rate adaptation. A: simulated (left) and experimental (right) APD adaptation in control (solid line) and for Na⁺/K⁺ pump inhibition (dotted line) by 10–20–30% in simulated human ventricular cardiomyocytes and by 0.2 (top) and 0.6 μM (bottom) strophanthin G (Stroph) in canine experiments. Experimental curves represent average over experiments. B: early afterdepolarization generated following CL increase from 600 to 1,000 ms for simulated 60% I_{NaK} inhibition. C–G: corresponding time course of [Ca²⁺], I_{r0}, I_{NaCa}, I_{CaL}, and calcium-dependent inactivation gate f_{calc} of I_{CaL}. See main text for definitions of abbreviations. V, voltage.
APD rate adaptation is defined as protracted when associated with EAD characterization using exponential functions. Based on our results, APD adaptation dynamics and EADs, which prevent its characterization using exponential functions. Based on our results, APD rate adaptation is defined as protracted when associated adaptation time compared with that in humans. APD adaptation dynamics are found in dogs, with a slightly longer adaptation time compared with that in humans.

In addition, NaK inhibition degrees > 40% lead to oscillations in APD adaptation dynamics and EADs, which prevent its characterization using exponential functions. Based on our results, APD rate adaptation is defined as protracted when associated adaptation time compared with that in humans. APD adaptation dynamics are found in dogs, with a slightly longer adaptation time compared with that in humans.

**Dynamics and Mechanisms of Ventricular HR Adaptation in Humans**

This study shows that simulated QTI and APD HR adaptation dynamics in humans are in good qualitative and quantitative agreement with the results reported in experimental and clinical studies (3, 18, 22, 29, 35, 36). The simulation results report two phases, fast and slow, in QTI and APD adaptation dynamics, as previously reported in human experiments (18, 29, 35, 36) and also confirmed in experiments performed in this study. The time constants for the two phases in human are $\tau_{\text{fast}} < 30$ s and $\tau_{\text{slow}} \approx 2$ min, respectively, in both simulations and experiments, in this study and in the literature (18, 36). Similar adaptation dynamics are found in dogs, with a slightly longer adaptation time compared with that in humans.

Our simulation results identify $I_{\text{CaL}}$ and $I_{\text{Ks}}$ properties as the main ionic determinants of the fast rate-dependent APD changes in humans, with $I_{\text{CaL}}$ inactivation (Fig. 5A) playing a major role, as reported in previous studies for humans (31), for guinea pigs and rabbits (39), and for canine Purkinje fibers (6). In addition, our results show that $I_{\text{Ks}}$ activation kinetics also contribute to the fast rate-dependent APD shortening (Fig. 5A), as previously suggested (8, 13, 14).

Importantly, we also demonstrate that [Na$^+$], dynamics play a key role in the slow phase of APD adaptation (Fig. 5). $I_{\text{NaK}}$ inhibition, as it occurs in ischemia and heart failure patients, results in slower [Na$^+$], dynamics and delayed APD accommodation. The importance of $I_{\text{NaK}}$ in the slow phase of APD adaptation was previously suggested in animal species such as dogs and guinea pigs (6, 10, 11, 14) but not in humans. Our study quantifies it and confirms it for humans. In addition, we show that it is primarily due to the role of $I_{\text{NaK}}$ in regulating [Na$^+$], dynamics, and, indirectly, [Ca$^{2+}$], dynamics through the Na$^+$/Ca$^{2+}$ exchanger, rather than to alterations in the electrogenic NaK current.

**Ventricular rate adaptation as an indicator of arrhythmic risk.** Following a thorough validation of the simulated rate adaptation dynamics described in Ventricular Rate Adaptation, computer simulations were used to explore the link between protracted HR adaptation and increased arrhythmic risk, as previously suggested (22, 35). The main preclinical arrhythmic risk biomarkers, namely, AP triangulation, probability of $I_{\text{CaL}}$ reactivation, and APDR, were evaluated for conditions that lead to delayed APD adaptation, to quantify risk of occurrence of repolarization instabilities such as EADs and/or alternans (5, 44).

As discussed in Ventricular Rate Adaptation, delayed APD adaptation could be caused by an increase in $\tau_{\text{fast}}$ (via a moderate reduction in $\tau_{\text{f}}$ or $\tau_{\text{xs}}$ severe $I_{\text{CaL}}$ maximal conductance block) or in $\tau_{\text{slow}}$ (via $I_{\text{NaK}}$ inhibition). Reduced $\tau_{\text{f}}$ values have been reported in dogs with chronic atrioventricular block (1), which exhibit a high propensity for EADs and Torsades de Pointes, whereas reduced $\tau_{\text{xs}}$ is caused by a mutation in the KCNQ1 gene that causes short QT syndrome and is associated with high sudden cardiac death rate (4). Our simulations also show that a less-pronounced initial AP rate adaptation is associated with an increased AP triangulation and, in the case of reduced $\tau_{\text{xs}}$, a higher probability of $I_{\text{CaL}}$ reactivation, which facilitates EAD formation (25, 27, 30). Our results are also consistent with experimental results showing that the low incidence of EADs observed following the administration of amiodarone could be related to the ability of the drug to slow $I_{\text{CaL}}$ (43) and decrease $\tau_{\text{fast}}$. Furthermore, in patients who benefit from amiodarone therapy, the efficacy of the drug has been explained by its ability to accelerate QTI rate adaptation (37).

Reduced $\tau_{\text{f}}$ or $\tau_{\text{xs}}$, and therefore increased $\tau_{\text{fast}}$, are also associated with APDR slopes flattening, consistent with previous studies (23). The potential of APDR slopes as arrhythmic risk predictors is somewhat controversial. Both experimental and theoretical studies have shown that steep restitution slopes facilitate a spiral wave breakup and a transition from ventricular tachycardia to fibrillation (20, 32). However, conditions associated with flat restitution slopes also allow wave break (9, 16) and could favor reentrant wave stability (17, 19). Thus large $\tau_{\text{fast}}$ values could also be associated with an increased
Ventricular rate adaptation mechanisms

Arrhythmic risk due to the increased likelihood of the establishment of reentrant activity.

Both our simulation and experimental results show that $I_{\text{NAK}}$ plays a key role in determining $\tau_{\text{slow}}$. Large $\tau_{\text{slow}}$ due to $I_{\text{NAK}}$ inhibition is associated with an increase in AP triangulation and in the likelihood of $I_{\text{CAL}}$ reactivation (Fig. 6), indicating an increased risk of EAD formation. Large $\tau_{\text{slow}}$ values are also associated with flat APDR slopes, which could favor the stability of reentrant circuits and thus could increase arrhythmic risk.

Our simulations show that, both in humans and dogs, EADs develop for 60% $I_{\text{NAK}}$ inhibition, a degree of inhibition observed in ischemic disease and heart failure patients treated with digitalis (7). In the experiments of $I_{\text{NAK}}$ inhibition with 0.2 or 0.6 $\mu$M strophanthin G performed in the present study, no EADs were observed; however, the degree of drug-induced $I_{\text{NAK}}$ inhibition is unknown and may be below 60%. Additionally, the lack of EADs in the experiments might be explained by the electrophysiological differences between the experimental (canine papillary muscle) and simulated preparations (canine Epi and human Endo/Mid/Epi tissue).

Limitations of the Study

In our study, a human ventricular model was used to explore ventricular rate adaptation dynamics and simulation predictions were validated using experimental and clinical data from the literature and in a limited set of experiments in humans performed in this study. Additional experiments and simulations were performed in dogs because of its similarities with humans in repolarization mechanisms. Our experimental and theoretical results obtained in dogs and humans are qualitatively similar, although quantitative differences exist that could be due to true animal species differences, differences in experimental conditions, or model limitations. First, differences exist in $I_{\text{K1}}$ and $I_{\text{Ks}}$ in canine versus human cardiac ventricular tissue (28), which would lead to differences in ventricular rate adaptation. Second, the human model (38) does not include a description of the late sodium current and its adaptation. Second, the human model (38) does not include a tissue (28), which would lead to differences in ventricular rate adaptation. These limitations of the study were validated using experimental and clinical data from the literature and in a limited set of experiments in humans.

DISCLOSURES

No conflicts to disclose.

REFERENCES


